Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Published:2020-12-16 Issue:4 Volume:27 Page:585-589
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Agrawal Manasi¹^ORCID,Brenner Erica J²,Zhang Xian²,Modesto Irene³,Woolcott John³,Ungaro Ryan C¹,Colombel Jean-Frederic¹,Kappelman Michael D²

Affiliation:

1. The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

2. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

3. Inflammation and Immunology, Global Medical Affairs, Pfizer Inc, New York, New York, USA

Funder

Helmsley Charitable Trust

National Center for Advancing Translational Sciences

Pfizer

Abbvie

Lilly

Genentech

Boehringer Ingelheim

Bristol Myers Squibb

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/27/4/585/36598975/izaa303.pdf

Reference10 articles.

1. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area;Richardson;Jama.,2020

2. Tofacitinib as induction and maintenance therapy for ulcerative colitis;Sandborn;N Engl J Med.,2017

3. The type I interferon response in COVID-19: implications for treatment;Lee;Nat Rev Immunol.,2020

4. Baricitinib restrains the immune dysregulation in severe COVID-19 patients;Bronte;J Clin Invest,2020

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The correlation between corona virus disease 2019 and alopecia areata: a literature review;Frontiers in Immunology;2024-07-03

2. Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset;BMC Rheumatology;2023-07-26

3. Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies;Inflammatory Bowel Diseases;2023-07-14

4. Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir;United European Gastroenterology Journal;2023-05-25

5. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2;MedComm;2023-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3